Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

The deal is the basis for Novo Nordisk's strategy to create capacities for the production of drugs for diabetes and obesity Ozempic and Wegovy, which, according to analysts, will become the ...